- Home
- REGN
as 08-22-2025 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 59.5B | IPO Year: | 1991 |
| Target Price: | $806.32 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 39.67 | EPS Growth: | 5.03 |
| 52 Week Low/High: | $476.49 - $1211.20 | Next Earning Date: | 08-01-2025 |
| Revenue: | $14,214,200,000 | Revenue Growth: | 5.38% |
| Revenue Growth (this year): | -3.84% | Revenue Growth (next year): | 6.65% |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Zacks
19 hours ago
The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk
Pharmaceutical Technology
2 days ago
J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub
Zacks
2 days ago
FDA Extends Review Period of REGN's Submission for Eylea HD
Pharmaceutical Technology
2 days ago
Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD
Reuters
2 days ago
J&J to invest $2 billion to boost US manufacturing as drug tariffs loom
GuruFocus.com
2 days ago
FDA Pushes Back Eylea HD Review; Regeneron Still Gains
MT Newswires
3 days ago
Regeneron Pharmaceuticals Says FDA Extends Action Dates for Eylea HD to Q4
GlobeNewswire
3 days ago
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.